Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3926763 | 0.94 | DPP4 (0.36) | KDRDPP4MAPK14EPHB4FGFR1 | |
| SCHEMBL3922932 | 0.92 | KDR (0.39) | KDRMAPK14EPHB4FGFR1CCNA2 | |
| SCHEMBL3933169 | 0.89 | MAPK14 (0.36) | KDRDPP4MAPK14EPHB4FGFR1 | |
| SCHEMBL3927416 | 0.89 | MAPK14 (0.36) | KDRDPP4MAPK14EPHB4FGFR1 | |
| SCHEMBL14395970 | 0.87 | KDR (0.32) | KDRMAPK14EPHB4FGFR1CCNA2 | |
| SCHEMBL5914286 | 0.85 | KDR (0.36) | KDRMAPK14EPHB4FGFR1CYP3A4 | |
| SCHEMBL5914283 | 0.85 | KDR (0.36) | KDRMAPK14EPHB4FGFR1CYP3A4 | |
| SCHEMBL4004025 | 0.81 | DPP4 (0.36) | KDRDPP4MAPK14EPHB4FGFR1 | |
| SCHEMBL3924760 | 0.79 | HRH4 (0.43) | KDRDPP4EPHB4FGFR1CCNA2 | |
| SCHEMBL5914043 | 0.78 | CFD (0.38) | KDRMAPK14EPHB4FGFR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041118-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | claimed |
| EP-2041118-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | disclosed |